Pfizer Chantix Nitrosamine Class Action Settlement
Pfizer · Chantix smoking-cessation drug · Settlement Reached
About this case
Pfizer agreed to pay $44 million to resolve a consumer class-action lawsuit alleging that its smoking-cessation drug Chantix contained an undisclosed nitrosamine. Pfizer denies wrongdoing, and the matter has reached a settlement.
Case overview
- Defendant company
- Pfizer
- Product or service
- Chantix smoking-cessation drug
- Court case number
- 22-MD-3050 (KPF); 22-MC-3050 (S.D.N.Y.)
- Case status
- Settlement Reached
- Lawsuit type
- Consumer
- Reported harm
- Product Defect
Important dates
- settlement claim
Participation information
Settlement Claim
Individuals and third-party payors who paid any amount for retail purchases of branded Chantix in the United States or its territories from 2015-09-29 through 2021-09-17 may be included, subject to the settlement’s detailed eligibility terms.
Consumers had to submit the official online Consumer Claim Form or mail the completed form to Chantix Settlement, c/o A.B. Data, Ltd., P.O. Box 173137, Milwaukee, WI 53217, by 2026-09-14. The form requests claimant contact information, the number of Chantix prescriptions purchased, and total out-of-pocket spending.
- Type
- Settlement Claim
- Status
- Deadline passed
- Total settlement amount
- $44,000,000
- Payout
- Consumer payments are distributed pro rata based on the amount each consumer paid for Chantix, capped at 20% of the Available Settlement Fund; no consumer claim may exceed the total amount paid for Chantix. The actual payment amount is variable and not stated as a fixed dollar amount.
- Reported proof requirement
- Unclear
Sources
- Pfizer Chantix Nitrosamine Class Action Settlement
Staten Island Advance ·